Updated
Reviewed
Jun. 03, 2021
Appendix B: Drug Characteristics Tables
Characteristics of CD4 Post-Attachment Inhibitor
Generic Name (Abbreviation) Trade Name |
Formulation | Dosing Recommendations | Serum Half-Life | Elimination/ Metabolic Pathway | Adverse Events |
---|---|---|---|---|---|
Ibalizumab (IBA) Trogarzo |
Trogarzo:
|
Trogarzo:
|
~64 hours | Not well defined |
Diarrhea Hypersensitivity, including anaphylaxis and infusion-related reactions have been reported. |
Key: IBA = ibalizumab; IV = intravenous |
Appendix B: Drug Characteristics Tables
Characteristics of CD4 Post-Attachment Inhibitor
Generic Name (Abbreviation) Trade Name |
Formulation | Dosing Recommendations | Serum Half-Life | Elimination/ Metabolic Pathway | Adverse Events |
---|---|---|---|---|---|
Ibalizumab (IBA) Trogarzo |
Trogarzo:
|
Trogarzo:
|
~64 hours | Not well defined |
Diarrhea Hypersensitivity, including anaphylaxis and infusion-related reactions have been reported. |
Key: IBA = ibalizumab; IV = intravenous |
Download Guidelines
- Section OnlyPDF (177.64 KB)
- Full GuidelinePDF (5.07 MB)
- Recommendations OnlyPDF (229.24 KB)
- Tables OnlyPDF (939.48 KB)